Advertisement
Travere Therapeutics, Inc.

Travere Therapeutics, Inc. (TVTX) Stock Overview

Explore Travere Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

TVTXNASDAQ
HealthcareBiotechnology
$55.15
$1.010(1.87%)
U.S. Market opens in 15h 9m
Advertisement

Travere Therapeutics, Inc. (TVTX)

Meyka AI Score

Z

Key Financials

Market Cap5.1B
P/E Ratio-236.51
EPS (TTM)$-0.50
ROE-0.27%
Fundamental Analysis

AI Price Forecasts

1 Month$50.84
3 Months$45.34
1 Year Target$44.85

TVTX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Travere Therapeutics, Inc. (TVTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 72.71, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $44.85.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -236.51 and a market capitalization of 5.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
1.87%
5-Day Change
12.32%
1-Month Change
30.50%
3-Month Change
98.95%
6-Month Change
59.81%
Year-to-Date (YTD) Change
44.33%
1-Year Change
285.39%
3-Year Change
216.95%
5-Year Change
267.42%
All-Time (Max) Change
3576.67%

Contact Information

888 969 7879
3611 Valley Centre Drive, San Diego, CA, 92130

Company Facts

3,850 Employees
IPO DateNov 8, 2012
CountryUS
Actively Trading

Frequently Asked Questions